Chen Jing, Hao Qingfei, Zhang Jing, Du Yanna, Chen Haoming, Cheng Xiuyong
Department of Neonatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Front Pediatr. 2023 Jan 25;10:1077137. doi: 10.3389/fped.2022.1077137. eCollection 2022.
This study's goal was to assess the short-term effect on body weight and multiple systems following intravitreal injections of ranibizumab and aflibercept for retinopathy of prematurity (ROP).
We retrospectively assessed infants with ROP who received intravitreal anti-vascular endothelial growth factor agents (VEGF) treatment at our hospital. They were classified into 2 groups based on the drugs administered: the intravitreal ranibizumab (IVR) group and the intravitreal aflibercept (IVA) group. The body weight (BW) gains for the pre-treatment week, the 1st week after treatment, and the 2nd week after treatment were compared for each group. Additionally, other parameters such as blood pressure, heart rate, oxygen concentration, volume of milk and output of urine at four time points were also measured. We used repeated measurement analysis of variance analyzed these data.
In total, 95 preterm infants were recruited, including 51 cases in the IVR group and 44 cases in the IVA group. The BW gain for the 1st week after treatment was significantly lower than the pre-treatment week in each group (< 0.05), while there was no decrease in weekly BW gain in the 2nd week after treatment compared with that pre-treatment week. Based on the comparison between groups, the BW gain in the IVR group was significantly higher than in the IVA group in the second post-treatment week. Repeated measurement analysis of variance showed that there were no significant differences in blood pressure, heart rate, oxygen concentration, volume of milk and output of urine in both groups over time.
IVR and IVA could have a short-term inhibitive effect on body weight gain in infants after treatment for ROP, whereas there is no significant impact on other systems.
本研究的目的是评估玻璃体内注射雷珠单抗和阿柏西普治疗早产儿视网膜病变（ROP）后对体重和多个系统的短期影响。
我们回顾性评估了在我院接受玻璃体内抗血管内皮生长因子药物（VEGF）治疗的ROP婴儿。根据所使用的药物将他们分为两组：玻璃体内注射雷珠单抗（IVR）组和玻璃体内注射阿柏西普（IVA）组。比较每组治疗前一周、治疗后第1周和治疗后第2周的体重增加情况。此外，还测量了四个时间点的其他参数，如血压、心率、氧浓度、奶量和尿量。我们使用重复测量方差分析来分析这些数据。
共纳入95例早产儿，其中IVR组51例，IVA组44例。每组治疗后第1周的体重增加明显低于治疗前一周（<0.05），而治疗后第2周的每周体重增加与治疗前一周相比没有下降。基于组间比较，治疗后第二周IVR组的体重增加明显高于IVA组。重复测量方差分析显示，两组的血压、心率、氧浓度、奶量和尿量随时间没有显著差异。
IVR和IVA治疗ROP后可能对婴儿体重增加有短期抑制作用，而对其他系统没有显著影响。
